Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Vivos Inc. (RDGL)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.0790+0.0064 (+8.74%)
At close: 03:22PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Performance Outlook
Previous Close0.0727
Open0.0749
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.0704 - 0.0809
52 Week Range0.0405 - 0.1395
Volume498,742
Avg. Volume479,443
Market Cap27.169M
Beta (5Y Monthly)2.12
PE Ratio (TTM)N/A
EPS (TTM)-0.0090
Earnings DateJun 29, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A

Subscribe to Yahoo Finance Plus to view Fair Value for RDGL

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • VIVOS INC
    PKI: Raising target price to $148.00PERKINELMER INC has an Investment Rating of HOLD; a target price of $148.000000; an Industry Subrating of High; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Medium.
    Rating
    Fair Value
    Economic Moat
    6 days agoArgus Research
View more
  • GlobeNewswire

    Vivos Inc. Provides Intellectual Property Protection Update

    Richland WA, May 12, 2022 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), Vivos Inc is pleased to report that it expanded its intellectual property protection on several fronts. Our patent team filed our particle patent in more than ten patent offices that collectively cover 63 countries throughout the world. This year we also filed a provisional patent number 63-299,930 giving us broader protection on recent and projected developments on both our hydrogel and our particle components. This week we

  • GlobeNewswire

    Vivos Inc Implements Multiple Patient IsoPet® Therapy Day

    Richland WA, April 21, 2022 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), Vivos Inc is pleased to announce a combined IsoPet® therapy schedule into one treatment day, allowing for one production run to provide multiple Isopet® therapies that are done in any one of our current three regional clinics at Vista Veterinary Hospital in Washington, the University of Missouri and John Hopkins University in Maryland. As the number of patients increases additional days will be scheduled. This schedule str

  • GlobeNewswire

    Vivos Inc. Enhances its Intellectual Property Protection

    Richland WA, Feb. 24, 2022 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), Vivos Inc is pleased to report that it filed its particle patent in several countries. Our new patent team filed the particle patent in the USA, Canada, the European Union, Japan, Australia, Brazil, China, India, South Korea, and the Russian Eurasian (Russia, Armenia, Azerbaijan, Belarus, Kazakhstan, Kyrgyzstan, Tajikistan, and Turkmenistan). Our patent counsel will also be pursuing amendments to increase the number of clai

Advertisement
Advertisement